Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Gaughan

Showing results (121-130 of 133) with videos related to

Pageof 14
Sort By:
American Journal of Industrial Medicine|June 10, 2014
Arterial stiffness, oxidative stress, and smoke exposure in wildland firefightersDenise M Gaughan, Paul D Siegel, Michael D Hughes, et al.
American Journal of Veterinary Research|November 26, 1998
Evaluation of mild lameness in horses trotting on a treadmill by clinicians and interns or residents and correlation of their assessments with kinematic gait analysisK G Keegan, D A Wilson, D J Wilson, et al.
Oncoimmunology|April 2, 2021
A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanomaCraig L Slingluff, Hassane M Zarour, Hussein Abdul-Hassan Tawbi, et al.
Public Health Reports (Washington, D.C. : 1974)|March 24, 2023
Tracking COVID-19 in the United States With Surveillance of Aggregate Cases and DeathsDiba Khan, Meeyoung Park, Jacqueline Burkholder, et al.
Journal for Immunotherapy of Cancer|January 22, 2021
Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63)Craig L Slingluff, Gina R Petroni, Kimberly A Chianese-Bullock, et al.
Journal of Occupational and Environmental Hygiene|February 27, 2014
Exposures and cross-shift lung function declines in wildland firefightersDenise M Gaughan, Chris A Piacitelli, Bean T Chen, et al.
Journal for Immunotherapy of Cancer|March 3, 2026
Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC)Emily K Ninmer, Gina R Petroni, Brian R Gastman, et al.
MMWR. Morbidity and Mortality Weekly Report|June 10, 2021
Decreases in COVID-19 Cases, Emergency Department Visits, Hospital Admissions, and Deaths Among Older Adults Following the Introduction of COVID-19 Vaccine - United States, September 6, 2020-May 1, 2021Athalia Christie, S Jane Henley, Linda Mattocks, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2018
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic MelanomaDouglas B Johnson, Jennifer Bordeaux, Ju Young Kim, et al.
Journal for Immunotherapy of Cancer|March 5, 2026
Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review studyElizabeth M Gaughan, Miso Kim, Ignacio Mendez, et al.
Pageof 14

Showing results (121-130 of 133) with videos related to

Sort By:
Pageof 14
American Journal of Industrial Medicine|June 10, 2014
Arterial stiffness, oxidative stress, and smoke exposure in wildland firefightersDenise M Gaughan, Paul D Siegel, Michael D Hughes, et al.
American Journal of Veterinary Research|November 26, 1998
Evaluation of mild lameness in horses trotting on a treadmill by clinicians and interns or residents and correlation of their assessments with kinematic gait analysisK G Keegan, D A Wilson, D J Wilson, et al.
Oncoimmunology|April 2, 2021
A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanomaCraig L Slingluff, Hassane M Zarour, Hussein Abdul-Hassan Tawbi, et al.
Public Health Reports (Washington, D.C. : 1974)|March 24, 2023
Tracking COVID-19 in the United States With Surveillance of Aggregate Cases and DeathsDiba Khan, Meeyoung Park, Jacqueline Burkholder, et al.
Journal for Immunotherapy of Cancer|January 22, 2021
Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63)Craig L Slingluff, Gina R Petroni, Kimberly A Chianese-Bullock, et al.
Journal of Occupational and Environmental Hygiene|February 27, 2014
Exposures and cross-shift lung function declines in wildland firefightersDenise M Gaughan, Chris A Piacitelli, Bean T Chen, et al.
Journal for Immunotherapy of Cancer|March 3, 2026
Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC)Emily K Ninmer, Gina R Petroni, Brian R Gastman, et al.
MMWR. Morbidity and Mortality Weekly Report|June 10, 2021
Decreases in COVID-19 Cases, Emergency Department Visits, Hospital Admissions, and Deaths Among Older Adults Following the Introduction of COVID-19 Vaccine - United States, September 6, 2020-May 1, 2021Athalia Christie, S Jane Henley, Linda Mattocks, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2018
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic MelanomaDouglas B Johnson, Jennifer Bordeaux, Ju Young Kim, et al.
Journal for Immunotherapy of Cancer|March 5, 2026
Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review studyElizabeth M Gaughan, Miso Kim, Ignacio Mendez, et al.
Pageof 14